In Vitro Cytotoxic Effects of Stabilizing Sugars within Human Intravenous Immunoglobulin Preparations against the Human Macrophage THP-1 Cell-line

References

• Rhoades, C.J., Williams, MA., Kelsey, S.M. and Newland, A.C. (2000) "Monocyte—macrophage system as targets for immunomodulation by intravenous immunoglobulin", Blood Reviews 14, 14–30.
   PubMed Web of Science ®Google Scholar
• Byrne, NP., Henry, J.C., Herrmann, D.N., Abdelhalim, A.N., Shrier, D.A., Francis, C.W. and Powers, J.M. (2002) "Neuro-pathologic findings in a Guillain—Barre patient with strokes after IVIg therapy", Neurology 59, 458–461.
   PubMed Web of Science ®Google Scholar
• Ballow, M. (1994) "Mechanisms of action of intravenous immune serum globulin therapy", Paediatric Infectious Diseases Journal 13, 806–811.
   PubMed Web of Science ®Google Scholar
• Manufacturers data sheet compendium.
   Google Scholar
• Arend, W.P. and Leung, D.Y. (1994) "IgG induction of IL-1 receptor antagonist production by human monocytes", Immmunological Reviews 139, 71–78.
   PubMed Web of Science ®Google Scholar
• Andersson, U., Bjork, L., Skansen, S.U. and Andersson, J. (1994) "Pooled human IgG modulates cytokine production in lymphocytes and monocytes", Immunological Reviews 139, 21–42.
   PubMed Web of Science ®Google Scholar
• Poutsiaka, D.D., Clark, B.D., Varmier, E. and Dinarello, C.A. (1991) "Production of IL-1 receptor antagonist and IL-113 by peripheral blood mononuclear cells is differentially regu-lated", Blood 78, 1275–1281.
   PubMed Web of Science ®Google Scholar
• Pereira, B.J., Poutsiaka, D.D., King, A., Strom, J.A., Narayan, G., Levey, A.S. and Dinarello, C.A. (1992) "In vitro production of IL-1 receptor antagonist in chronic renal failure, CAPD and HD", Kidney International 42, 1419–1424.
   PubMed Web of Science ®Google Scholar
• Shimozato, T., Iwata, M., Kawada, H. and Tamura, N. (1991) "Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3' 5'-mono-phosphate levels, resulting in suppression of tumor necrosis factor-a and interleukin-1 production", Immunology 72, 497–501.
   PubMed Web of Science ®Google Scholar
• Kaveri, S.T., Vassilev, T., Hurez, V, Lengagne, R., Cot, S., Pouletty, P., Glotz, D. and Kazatchkine, M. (1996) "Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg)", Journal of Clinical Investigation 97, 865–869.
   PubMed Web of Science ®Google Scholar
• Prasad, N.K., Papoff, G., Zeuner, A., Bonnin, E., Kazatchldne, M.D., Ruberti, G. and Kaveri, S.V. (1998) "Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway", Journal of Immunology 161, 3781–3790.
   PubMed Web of Science ®Google Scholar
• Achiron, A., Barak, Y., Goren, M., Gabbay, U., Miron, S., Rotstein, Z., Noy, S. and Sarova-Pinhas, I. (1996) "Intravenous immunoglobulin in multiple sclerosis: clinical and neuro-radiological results and implications for possible mechanisms of action", Clinical and Experimental Immunology 104, 67–70.
   PubMed Web of Science ®Google Scholar
• Aukrust, P., Froland, S.S., Liabakk, N., Muller, F., Nordoy, I., Haug, C. and Espevik, T. (1994) "Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo", Blood 84, 2136–2143.
   PubMed Web of Science ®Google Scholar
• Andersson, J., Skansén-Saphir, U., Sparrelid, E. and Andersson, U. (1996) "Intravenous immune globulin affects cytokine production in T lymphocytes and monocyte/macro-phages", Clinical and Experimental Immunology 104, 10–20.
   PubMed Web of Science ®Google Scholar
• Ruis De Sousa, V, Carreno, M., Kaveri, S.V., Ledur, A., Sadeghi, H., Cavaillon, J., Kazatchkine, M.D. and Haeffner-Cavaillon, N. (1995) "Selective induction of IL-1ra and IL-8 in human monocytes by normal polyspecific Ig (IVIg)", European Journal of Immunology 25, 1267–1273.
   PubMed Web of Science ®Google Scholar
• Alder, L.B., Morgan, L.A. and Spickett, G.P. (1996) "Contri-bution of agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro", Scandinavian Journal of Immunology 44, 585–591.
   PubMed Web of Science ®Google Scholar
• Brannagan, T.H., Nagle, K.J., Lange, D.J. and Rowland, L.P. (1996) "Complications of intravenous immune globulin treatment in neurologic disease", Neurology 47, 674–677.
   PubMed Web of Science ®Google Scholar
• Dwyer, J.M. (1992) "Manipulating the immune system with immune globulin", New England Journal of Medicine 326, 107–116.
   PubMed Web of Science ®Google Scholar
• Buckley, R. and Schiff, R.I. (1991) "The use of intravenous immune globulin in immunodeficiency diseases", New England Journal of Medicine 325, 110–117.
   PubMed Web of Science ®Google Scholar
• Ahsan, N., Palmer, B.F., Wheeler, D., Greenlee, R.G. and Toto, R.D. (1994) "Intravenous immunoglobulin-induced osmotic nephrosis", Archives of Internal Medicine 154, 1985–1987.
   PubMed Web of Science ®Google Scholar
• Winward, D.B. and Brophy, M.T. (1995) "Acute renal failure after administration of intravenous immunoglobulin: Review of the literature and case report", Pharmacotherapy 15, 765–772.
   PubMed Web of Science ®Google Scholar
• Cayco, A.V., Perazella, M.A. and Hayslett, J.P. (1997) "Renal insufficiency after intravenous immune globulin therapy: A report of two cases and an analysis of the literature", Journal of the American Society of Nephrology 8, 1788–1794.
   PubMed Web of Science ®Google Scholar
• Hansen-Schmidt, S., Silomon, J. and Keller, F. (1996) "Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis", American Journal of Kidney Diseases 28, 451–453.
   PubMed Web of Science ®Google Scholar
• Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.H. and French, L.E. (1998) "Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin", Science 282, 490–493.
   PubMed Web of Science ®Google Scholar
• Exberg, C., Nordstrom, E., Skansen-Saphir, U., Mansouri, M., Raqib, R., Sundqvist, V.A. and Fernandez, C. (2001) "Human polyspecific immunoglubulin for therapeutic use induces p21 /WAF-1 and long-term survival", Human Immunology 62, 215–227.
   PubMed Web of Science ®Google Scholar
• Williams, M.A., Rhoades, C.J., Lewis, A., Newland, A.C. and Kelsey, S.M. (1999) "IVIg inhibits macrophage nitric oxide synthesis and activation-induced apoptosis: Relevance of inducible nitric oxide synthase and the transcription factors NF-kappa B and AP-1", British Journal of Haematology 105\(Supplement 1), 51.
   Google Scholar
• Gaines, A., Varricchio, F., Kapit, R., Pierce, L.R., Scott, D. and Finlayson, J. (1999) "Renal insufficiency and failure associated with immune globulin intravenous therapy in the United States, 1985-1998", MMWR Weekly 48, 518–521.
   PubMedGoogle Scholar
• Levy, J.B. and Pusey, C.D. (2000) "Nephrotoxicity of intravenous immunoglobulin", Quarterly Journal of Medicine 93, 751–755.
   Google Scholar
• Laidlaw, S., Bainton, R., Wilkie, R. and Makris, M. (1999) "Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin", Haemophilia 5, 270–272.
   PubMed Web of Science ®Google Scholar
• Haskin, J.A., Warner, D.J. and Blank, D.U. (1999) "Acute renal failure after large doses of intravenous immune globulin", Annals of Pharmacotherapy 33, 800–803.
   PubMed Web of Science ®Google Scholar
• McColl, M.D., Omran, A., Walker, ID. and Lowe, G.D. (1999) "Acute renal failure complicating high-dose intravenous immunoglobulin therapy for acquired haemophilia", Haemo-philia 5, 124–126.
   PubMed Web of Science ®Google Scholar
• Ahsan, N., Wiegand, L.A., Abendroth, CS. and Manning, E.C. (1996) "Acute renal failure following immunoglobulin therapy", American Journal of Nephrology 16, 532–536.
   PubMed Web of Science ®Google Scholar
• Keith, N., Power, M. and Peterson, R. (1933) "The renal excretion of sucrose when injected intravenously in man", American Journal of Physiology 105, 60–61.
   Google Scholar
• Rigdon, R. and Cardwell, E. (1942) "Renal lesions after the intravenous injection of a hypertonic solution of sucrose", Archives of Internal Medicine 69, 670–690.
   Google Scholar
• Woodruff, R.K., Grigg, A.P., Firkin, F.C. and Smith, II. (1986) "Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients", Lancet 2(8500), 217–218.
   PubMed Web of Science ®Google Scholar
• Elkagam, O., Paran, D., Milo, R., Davidovitz, Y., Almozino-Sarafian, D., Zeltser, D., Yaran, M. and Caspi, D. (2000) "Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases", Annals of the Rheumatic Diseases 59, 77–80.
   PubMed Web of Science ®Google Scholar
• Duhem, C., Dicato, M.A. and Ries, F. (1994) "Side effects of intravenous immune globulins", Clinical and Experimental Immunology 97, 79–83.
   PubMed Web of Science ®Google Scholar